United States Cardiac Rhythm Management Devices Market Outlook to 2033 - Cardiac Resynchronisation Therapy (CRT), Implantable Cardioverter Defibrillators (ICD) and Others

1.1 List of Tables
1.2 List of Figures

2.1 What Is This Report About?
2.2 Cardiac Rhythm Management Devices Market Segmentation
2.3 Definitions of Markets Covered in the Report

3.1 Cardiac Rhythm Management Devices Market, United States, Revenue ($m), 2018-2033
3.1.1 Cardiac Resynchronisation Therapy (CRT) Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.2 Implantable Cardioverter Defibrillators (ICD) Market, United States, Revenue ($m), by Segment, 2018-2033
3.1.3 Pacemakers Market, United States, Revenue ($m), by Segment, 2018-2033
3.2 Cardiac Rhythm Management Devices Market, United States, Volume (Units), 2018-2033
3.2.1 Cardiac Resynchronisation Therapy (CRT) Market, United States, Volume (Units), by Segment, 2018-2033
3.2.2 Implantable Cardioverter Defibrillators (ICD) Market, United States, Volume (Units), by Segment, 2018-2033
3.2.3 Pacemakers Market, United States, Volume (Units), by Segment, 2018-2033
3.3 Cardiac Rhythm Management Devices Market, United States, Average Price ($), 2018-2033
3.4 Cardiac Rhythm Management Devices Market, United States, Distribution Share by Revenue ($m), 2023
3.5 Cardiac Rhythm Management Devices Market, United States, Company Share by Revenue ($m), 2023

4.1 Medtronic Plc
4.1.1 Company Overview
4.2 Abbott Laboratories
4.2.1 Company Overview
4.3 Boston Scientific Corp
4.3.1 Company Overview
4.4 Biotronik SE & Co KG
4.4.1 Company Overview

6.1 Debt Offerings
6.1.1 iRhythm Technologies Prices 1.50% Convertible Senior Notes Due 2029 for USD575 Million
6.2 Equity Offerings
6.2.1 CardieX Files to Raise Approximately USD10.66 Public Offering of American Depositary Shares
6.3 Private Equity
6.3.1 GTCR to Acquire Surmodics for Approximately USD627 Million

7.1 Corporate Communications
7.1.1 Jun 18, 2024: Aviva McPherron Joins Orthofix as President of Global Operations and Quality
7.1.2 Jun 12, 2024: Nkgen Biotech Presents Phase 1 Data on SNK02 Allogeneic Nk Cell Therapy for Solid Tumors at the 6th Annual Allogeneic Cell Therapies Summit 2024
7.1.3 Jun 11, 2024: Orthofix Names Julie Dewey Chief Investor Relations and Communications Officer; Max Reinhardt Begins as President of Global Spine
7.1.4 May 23, 2024: Orthofix Names Max Reinhardt President of Global Spine Business
7.1.5 Apr 16, 2024: Orthofix Names Andres Cedron as New Chief Legal Officer
7.1.6 Apr 09, 2024: BriaCell Showcases Data Demonstrating Unmatched PFS and Clinical Efficacy in ADC Resistant and CNS Metastatic Breast Cancer at the 2024 AACR
7.1.7 Mar 18, 2024: Lucas Vitale Joins Orthofix as Chief People and Business Operations Officer
7.1.8 Feb 22, 2024: Ventyx Biosciences to Present Results of the Phase 2 Trial of VTX002 in Ulcerative Colitis at the 19th Congress of the ECCO
7.1.9 Feb 05, 2024: Ultima Genomics to Launch UG 100 System and Present Data at AGBT
7.1.10 Jan 31, 2024: CVRx Announces Appointment of Kevin Hykes as President and Chief Executive Officer
7.1.11 Dec 12, 2023: Orthofix Announces Agreement with Engine Capital and Appointment of Three New Independent Directors to Further Advance Position as Leading Global Spine and Orthopedics Company
7.1.12 Nov 07, 2023: New Research Shows High Accuracy of Precivity Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease
7.1.13 Oct 04, 2023: Stereotaxis Robotic Technology to be Featured during 7th Annual Meeting of the Society for Cardiac Robotic Navigation
7.1.14 Sep 12, 2023: Orthofix Announces Leadership Changes
7.1.15 Jul 17, 2023: 3Dio Receives 510(k) Clearance for Lumos 3DX
7.2 Financial Announcements
7.2.1 May 13, 2024: Stereotaxis Reports 2024 First Quarter Financial Results
7.2.2 Apr 23, 2024: Orthofix Schedules First Quarter 2024 Earnings Release and Conference Call for May 7, 2024
7.2.3 Apr 16, 2024: CVRx to Report First Quarter 2024 Financial and Operating Results and Host Conference Call on April 30th, 2024
7.2.4 Mar 22, 2024: Concha Receives FDA 510(k) Clearance for Sol Hearing Aid (CL-1001)
7.2.5 Feb 21, 2024: Orthofix Schedules Fourth Quarter and Full Year 2023 Earnings Release and Conference Call for March 5, 2024
7.2.6 Feb 16, 2024: Denali Therapeutics : Regulation FD Disclosure
7.2.7 Jan 31, 2024: Boston Scientific Announces Results for Fourth Quarter and Full Year 2023
7.2.8 Jan 16, 2024: Surmodics to Report First Quarter of Fiscal 2024 Financial Results on February 1
7.2.9 Jan 08, 2024: iRhythm Technologies Shares Preliminary Fourth Quarter 2023 Highlights and Business Update at the 42nd Annual J.P. Morgan Healthcare Conference
7.2.10 Jan 05, 2024: Boston Scientific Announces Conference Call Discussing Fourth Quarter 2023 Results
7.2.11 Nov 08, 2023: Orthofix Reports Third Quarter 2023 Results
7.2.12 Oct 26, 2023: Boston Scientific Announces Results for Third Quarter 2023
7.2.13 Oct 24, 2023: Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Anchored Immunotherapy Agent, ANK-101 in Solid Tumors
7.2.14 Oct 16, 2023: Hypera Pharma's Nebacetin Expands Territory Into the Children’s Segment With Nebacetin Baby, a Line of Ointments Against Diaper Rash
7.2.15 Oct 12, 2023: CVRx to Report Third Quarter 2023 Financial and Operating Results and Host Conference Call on October 26th, 2023
7.2.16 Aug 25, 2023: Blackford and Ligence Announce Echocardiography AI Partnership
7.2.17 Aug 09, 2023: Fluidai’s Artificial Intelligence-Powered Postsurgical Monitor, Stream Platform, Launches Globally
7.3 Government and Public Interest
7.3.1 Aug 29, 2023: iRhythm Technologies to Participate in Two Investor Conferences in September
7.3.2 Aug 02, 2023: Sentinel Medical Technologies Addresses IAP Transducer Shortage With Traumaguard
7.4 Legal And Regulatory
7.4.1 Jun 11, 2024: KeViRx, Awarded $1.99 Million from the U.S. Department of Defense's Peer Reviewed Medical Research Program
7.4.2 May 14, 2024: Valcare Medical Announces Enrollment of First Two Patients in AMEND TS EU Pilot Study
7.4.3 Dec 11, 2023: Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in R/R MM at the 65th ASH Annual Meeting
7.5 Other Significant Developments
7.5.1 Feb 12, 2024: Tyber Medical Acquires FDA Clearance for Proximal Tibia Plating System
7.5.2 Jan 09, 2024: Orthofix Medical Announces Preliminary 2023 Fourth Quarter and Full-Year Net Sales Results
7.5.3 Dec 20, 2023: ResMed Notifies Customers About Updated Instructions and Labeling for Masks with Magnets Due to Potential Interference with Certain Medical Devices
7.6 Product News
7.6.1 May 08, 2024: Eli Lilly : Announcement of Approval Submission And Marketing Alliance in Japan For Tirzepatide as a Drug for Obesity Disease
7.7 Strategy And Business Planning
7.7.1 Jun 20, 2023: Shenzhen Mindray Bio-Medical Electronics Receives an Additional 510(k) Clearance for M11 Diagnostic Ultrasound System

8.1 Research Methodology
8.1.1 Coverage
8.1.2 Secondary Research
8.1.3 Primary Research
8.1.4 Market Modeling and Forecasting
8.1.5 Company Share Analysis
8.1.6 Distribution Share Analysis
8.1.7 Benchmarking
8.2 the analyst Consulting
8.3 Contact the Publisher
8.4 Disclaimer

Table 1: Cardiac Rhythm Management Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 2: Cardiac Resynchronisation Therapy (CRT) Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 3: Implantable Cardioverter Defibrillators (ICD) Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 4: Pacemakers Market, United States, Revenue ($m), USD Constant, 2018-2033
Table 5: Cardiac Rhythm Management Devices Market, United States, Volume (Units), 2018-2033
Table 6: Cardiac Resynchronisation Therapy (CRT) Market, United States, Volume (Units), 2018-2033
Table 7: Implantable Cardioverter Defibrillators (ICD) Market, United States, Volume (Units), 2018-2033
Table 8: Pacemakers Market, United States, Volume (Units), 2018-2033
Table 9: Cardiac Rhythm Management Devices Market, United States, Average Price ($), 2018-2033
Table 10: Cardiac Rhythm Management Devices Market, United States, Distribution Share by Revenue ($m), USD Constant, 2023
Table 11: Cardiac Rhythm Management Devices Market, United States, Company Share by Revenue ($m), USD Constant, 2023
Table 12: Cardiac Rhythm Management Devices Market Pipeline Products
Table 13: iRhythm Technologies Prices 1.50% Convertible Senior Notes Due 2029 for USD575 Million
Table 14: CardieX Files to Raise Approximately USD10.66 Public Offering of American Depositary Shares
Table 15: GTCR to Acquire Surmodics for Approximately USD627 Million
Table 16: Total Number of Primary Research Participants, Cardiovascular devices Market, by Country

Figure 1: Cardiac Rhythm Management Devices Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 2: Cardiac Resynchronisation Therapy (CRT) Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 3: Implantable Cardioverter Defibrillators (ICD) Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 4: Pacemakers Market, United States, Revenue ($m), USD Constant, 2018-2033
Figure 5: Cardiac Rhythm Management Devices Market, United States, Volume (Units), 2018-2033
Figure 6: Cardiac Resynchronisation Therapy (CRT) Market, United States, Volume (Units), 2018-2033
Figure 7: Implantable Cardioverter Defibrillators (ICD) Market, United States, Volume (Units), 2018-2033
Figure 8: Pacemakers Market, United States, Volume (Units), 2018-2033
Figure 9: Cardiac Rhythm Management Devices Market, United States, Company Share (%) 2023